ZLAB - One Good One Bad News For Bristol Myers Squibb's Marketed Drugs: Details | Benzinga
Thursday, Bristol Myers Squibb & Co (NYSE:BMY) announced an update following the initial analysis of results from the first of two induction studies in the Phase 3 YELLOWSTONE trial program of Zeposia (ozanimod) in adult patients with moderate to severe active Crohn’s disease.
The study did not meet its primary endpoint of clinical remission at Week 12.
The safety profile of Zeposia in this study was consistent with that observed in previously reported trials.
The company will complete a full evaluation of the YELLOWSTONE trial data.
Zeposia is approved for relapsing forms of multiple sclerosis and adults with moderately to severely active ulcerative colitis.
Today, Bristol Myers Squibb announced results from the Phase 3 KRYSTAL-12 study, evaluating Krazati (adagrasib) as ...